What it's for (Indications)
- Cyclizine (e.
- g.
- , Medizine) is a potent antihistaminic agent primarily indicated for the prevention and symptomatic relief of nausea, vomiting, and dizziness associated with various etiologies.
- This includes, but is not limited to, the management of motion sickness, where it is highly effective in mitigating the distressing symptoms experienced during travel.
- Furthermore, it plays a crucial role in the post-operative setting for the treatment of established nausea and vomiting, helping to improve patient comfort and reduce complications.
- It is also frequently utilized in the management of vertigo and conditions like Ménière's disease, where it helps alleviate the accompanying sensations of spinning, imbalance, and associated emesis.
- Its broad spectrum of antiemetic and antivertiginous activity makes it a valuable therapeutic option in clinical practice, addressing both acute and chronic symptoms effectively across a diverse patient population.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage of cyclizine (e.g., Medizine) varies based on the patient's age, the specific indication, and the route of administration. For adults, in the prevention of motion sickness, a common oral dose is 50 mg taken approximately 20 to 30 minutes prior to anticipated travel, with subsequent doses of 50 mg every 4 to 6 hours if symptoms persist or re-emerge, not exceeding a maximum daily dose of 200 mg. For the treatment of established nausea and vomiting, including post-operative scenarios, intramuscular or intravenous administration of 50 mg up to three times daily may be employed, particularly when oral intake is compromised. Pediatric dosing must be carefully considered and is generally not recommended for very young children without specific medical advice due to their increased susceptibility to side effects. It is imperative that healthcare professionals determine the most appropriate dosage regimen, considering individual patient factors such as renal or hepatic impairment, to optimize efficacy and minimize potential adverse effects. |
Safety & Warnings
Common Side Effects
- Cyclizine (e.
- g.
- , Medizine), like all medications, can elicit a range of side effects, primarily due to its antihistaminic and anticholinergic properties.
- The most frequently reported adverse reactions include central nervous system (CNS) effects such as drowsiness, sedation, and fatigue, which can impair cognitive and motor functions, making tasks requiring alertness (e.
- g.
- , driving, operating machinery) hazardous.
- Other common anticholinergic effects encompass dry mouth, blurred vision (due to cycloplegia), urinary retention, and constipation.
- Less common but potentially serious side effects include paradoxical CNS stimulation, particularly in children, which may manifest as excitability, restlessness, or insomnia.
- Cardiovascular effects such as tachycardia or hypotension, especially with parenteral administration, have also been reported.
- Rare but significant adverse events can include hypersensitivity reactions, headaches, dizziness, and very rarely, extrapyramidal symptoms or hallucinations.
- Patients should be counselled to report any unusual or severe symptoms to their healthcare provider promptly.
Serious Warnings
- Black Box Warning: **Serious Warnings: Central Nervous System Depression and Anticholinergic Effects** While cyclizine (e.g., Medizine) does not carry a formal FDA Black Box Warning, healthcare professionals and patients must be acutely aware of its potential for serious adverse effects, primarily stemming from its central nervous system (CNS) depressant and anticholinergic properties. **CNS Depression:** Cyclizine can cause significant drowsiness, sedation, and impaired mental alertness. This effect is dose-dependent and can be exacerbated by concomitant use of other CNS depressants, including alcohol, opioids, benzodiazepines, and other sedative medications. Patients must be strongly cautioned against engaging in activities requiring full mental acuity, such as driving a vehicle or operating heavy machinery, until they have established how cyclizine affects them. Concomitant use of cyclizine with other CNS depressants may lead to profound sedation, respiratory depression, and potentially life-threatening complications. Close monitoring is essential if co-administration is unavoidable. **Anticholinergic Effects:** Cyclizine exerts potent anticholinergic effects that can lead to significant clinical consequences. These include, but are not limited to, acute angle-closure glaucoma, urinary retention (particularly in patients with prostatic hypertrophy or bladder outlet obstruction), and exacerbated gastrointestinal motility disorders (e.g., paralytic ileus, pyloric stenosis). These effects can be severe and require immediate medical intervention. Patients with pre-existing conditions susceptible to anticholinergic exacerbation should be carefully evaluated, and cyclizine should be used with extreme caution or avoided entirely in such cases. The elderly are particularly vulnerable to these adverse effects, including increased risk of falls, confusion, and cognitive impairment. **Potential for Abuse:** Although uncommon, cyclizine has a potential for abuse, particularly at high doses, due to its mild euphoric and hallucinogenic effects. Healthcare providers should be mindful of this potential, especially in individuals with a history of substance abuse. Patients should strictly adhere to prescribed dosages and not exceed them.
- Cyclizine (e.
- g.
- , Medizine) should be administered with caution in several patient populations due to its pharmacological profile.
- Its sedative properties necessitate vigilance, advising patients against engaging in activities requiring high levels of concentration or motor coordination, such as driving or operating heavy machinery, until they understand their individual response to the drug.
- Concomitant use with alcohol or other central nervous system depressants (e.
- g.
- , opioids, benzodiazepines) can significantly potentiate sedative effects, leading to profound respiratory depression or excessive somnolence.
- Due to its anticholinergic activity, cyclizine should be used with extreme prudence in patients with conditions aggravated by antimuscarinic agents, such as prostatic hypertrophy, angle-closure glaucoma, or conditions leading to urinary retention or gastrointestinal obstruction (e.
- g.
- , pyloric stenosis, paralytic ileus).
- Patients with epilepsy or seizure disorders should also be monitored carefully as antihistamines can lower the seizure threshold.
- Furthermore, individuals with severe hepatic or renal impairment may require dose adjustments due to altered drug metabolism and excretion, increasing the risk of accumulation and adverse effects.
- The potential for dependence and abuse, though rare, should be considered, especially with high doses.
How it Works (Mechanism of Action)
Cyclizine (e.g., Medizine) exerts its therapeutic effects primarily through its action as a histamine H1-receptor antagonist. This antagonism occurs in various central nervous system (CNS) sites, particularly within the brainstem, which includes the chemoreceptor trigger zone (CTZ) and the vestibular nuclei. By blocking H1 receptors, cyclizine effectively inhibits the stimulation of these areas, which are crucial in initiating and coordinating the vomiting reflex. Furthermore, cyclizine possesses significant anticholinergic (antimuscarinic) properties. These anticholinergic actions contribute substantially to its antiemetic and antivertiginous efficacy by blocking muscarinic receptors in the vestibular system, thereby reducing the excitability of the labyrinthine apparatus and interrupting nerve impulse transmission along the vestibular-cerebellar pathways. This dual mechanism of action allows cyclizine to effectively counteract the diverse stimuli that lead to nausea, vomiting, and vertigo, providing comprehensive relief from these distressing symptoms by centrally dampening the emetic pathways and peripherally stabilizing vestibular input.